New Research Explores Gaps in Health Plan Implementation of FDA Label Revisions

Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA ...

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism

BioMarin’s Voxzogo (vosoritide) won FDA approval in paediatric achondroplasia in November 2021 and secured a label extension ...

GLP-1s may increase risk of osteoporosis and gout, new research finds

About 4% of GLP-1 users developed osteoporosis, compared with a little over 3% of nonusers — an increased risk of about 30%.
KUOW

Ivermectin is making a post-pandemic comeback, among cancer patients

The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative ...
Healio

FDA approves label expansion for Zepbound to be used with Eli Lilly’s KwikPen

The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...

FDA cracks down on weight-loss drug alternatives as thousands sickened in Maryland

Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened ...